ゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬市場：2024年～2031年

レポート概要

ゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬の世界市場は、2023年に16億4,000万米ドルに達し、2031年には33億9,000万米ドルに達すると予測され、予測期間2024-2031年のCAGRは9.6%で成長する見込みです。

ゴナドトロピンは、卵巣および精巣機能を調節するペプチドホルモンであり、正常な成長、性的発達、生殖に不可欠です。ヒト性腺刺激ホルモンには、下垂体で作られる卵胞刺激ホルモン（FSH）と黄体形成ホルモン（LH）、胎盤で作られる絨毛性ゴナドトロピン（hCG）などがあります。ゴナドトロピンホルモン放出ホルモン（GnRH）は生殖軸の重要な調節因子です。ゴナドトロピン放出ホルモン（GnRH）の拍動性分泌は、性腺刺激ホルモンである卵胞刺激ホルモンと黄体形成ホルモンの分泌パターンを決定し、性腺における内分泌機能と配偶子の成熟を調節します。

ゴナドトロピン放出ホルモン（GnRH）作動薬は、卵巣や精巣が性ホルモンを分泌するのを妨げる合成物質です。性ホルモンの産生に必要な他のホルモンを阻害することで作用します。ゴナドトロピン放出ホルモン（GnRH）拮抗薬は、下垂体による卵胞刺激ホルモン（FSH）や黄体形成ホルモン（LH）などのホルモンの生成を阻害する薬剤の一種です。

市場力学：

促進要因

卵巣がんおよび前立腺がんの有病率の増加

卵巣がんと前立腺がんの有病率の増加は、市場の成長を促進します。例えば、英国では、毎年平均52,000人以上の男性が前立腺がんと診断されており、これは1日あたり144人の男性に相当します。イギリスでは毎年44,000人以上の男性が前立腺がんと診断されています。イギリスでは毎年10,000人以上の男性が前立腺がんで死亡しています。スコットランドでは毎年3,800人以上の男性が前立腺がんと診断されます。スコットランドでは毎年1,000人以上の男性が前立腺がんで死亡しています。ウェールズでは毎年2,800人以上の男性が前立腺がんと診断されます。ウェールズでは毎年約630人の男性が前立腺がんで死亡しています。

さらに、世界がん研究基金インターナショナルによると、卵巣がんは世界で18番目に多いがんです。女性では8番目に多いがんです。2022年には324,603人以上の卵巣がん患者が新たに発生しました。

206,956人の女性が卵巣がんで死亡しました。卵巣がんの新規症例発生率は、女性10万人当たり年間10.2人です。死亡率は女性10万人当たり年間6.0人でした。女性の約1.1％が生涯のある時点で卵巣がんと診断されます。

制約

ゴナドトロピン放出ホルモン作動薬および拮抗薬に関連する副作用やリスクなどの要因が、市場を阻害すると予想されます。場合によっては、ゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬の使用により、ほてり、女性化乳房、疲労、体重増加、体液貯留、勃起不全、性欲減退、骨密度の低下、月経不順が生じます。

市場セグメンテーション

世界のゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬市場は、薬剤タイプ、用途、エンドユーザー、地域に基づいてセグメント化されます。

GnRH作動薬セグメントは、世界のゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬市場シェアの約43.6％を占めています。

予測期間中、GnRH作動薬セグメントが最大の市場シェアを占めると予想されます。この分野では、技術的進歩が市場を牽引します。

ゴナドトロピン放出ホルモン（GnRH）作動薬は、卵子を発育させないよう脳にシグナルを送ることで、卵巣のスイッチを一時的に切る働きをします。これにより、卵巣はエストロゲンとプロゲステロンの産生を停止し、多くの健康状態を改善することができます。ゴナドトロピン放出ホルモン（GnRH）作動薬は、卵巣がエストロゲンを産生するのを止めることで、エストロゲン受容体陽性の乳がん細胞の治療に役立ちます。ゴナドトロピン放出ホルモン（GnRH）作動薬は、子宮内膜切除術の前に子宮内膜を薄くするのを助けることができます。

例えば、2023年6月、米国食品医薬品局は、症候性子宮内膜症の治療において、酢酸リュープロリドデポ製剤、ゴセレリンインプラント、ナファレリン経鼻製剤の使用を、単独投与で最長6カ月まで承認しました。

地域別市場分析

北米は、ゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬の世界市場シェアの約49.3％を占めています。

予測期間中、北米地域が最大の市場シェアを占めると予想されます。前立腺癌や卵巣癌、子宮内膜症の発生率の増加と、この地域における技術の進歩が市場の成長を後押ししています。

例えば、米国保健福祉省によると、子宮内膜症は、子宮（子宮）の内膜に似た組織が子宮の外で増殖することで起こります。15歳から44歳のアメリカ人女性の11％以上が罹患している可能性があります。30代から40代の女性に広くみられ、妊娠しにくくなることもあります。子宮内膜症にはいくつかの治療法があり、症状を改善し、妊娠の可能性を高めることができます。子宮内膜症は、25～40歳のアメリカ人女性の2～10％が罹患していると推定されています。

さらに、米国疾病予防管理センター（Centers for Disease Control and Prevention）が発表した論文によると、入手可能な最新のデータに基づき、米国では2022年に33,363人の男性が前立腺がんで死亡しています。前立腺がんの新規罹患率は、男性10万人当たり年間116.5人です。死亡率は男性10万人当たり年間19.0人でした。男性の約12.8％が生涯のある時点で前立腺がんと診断されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 前立腺がんと卵巣がんの有病率の増加
  • 抑制要因
    • ゴナドトロピン放出ホルモン（GnRH）作動薬および拮抗薬に関する副作用とリスク
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 薬剤タイプ別

• GnRH作動薬
• GnRH拮抗薬

第7章 用途別

• 婦人科領域
• 腫瘍学
• その他

第8章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Bayer AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Ferring
• Abbvie Inc.
• AstraZeneca
• Merck KGaA
• Ipsen Pharma
• TerSera Therapeutics LLC
• Takeda Pharmaceutical Company Limited
• Cipla
• Lupin（*LIST NOT EXHAUSTIVE）

第12章 付録

Report Overview

The Global Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists Drugs Market reached US$ 1.64 billion in 2023 and is expected to reach US$ 3.39 billion by 2031, growing at a CAGR of 9.6% during the forecast period 2024-2031.

The gonadotropins are peptide hormones that regulate ovarian and testicular function and are essential for normal growth, sexual development, and reproduction. The human gonadotropins include follicle-stimulating hormone (FSH) and luteinizing hormone (LH) which are made in the pituitary, and chorionic gonadotropin (hCG) which is made by the placenta. Gonadotropin hormone-releasing hormone (GnRH) is the key regulator of the reproductive axis. Its pulsatile secretion determines the pattern of secretion of the gonadotropins follicle-stimulating hormone and luteinizing hormone, which then regulate both the endocrine function and gamete maturation in the gonads.

Gonadotropin-releasing hormone (GnRH) agonists are synthetic substances that prevent the ovaries and testicles from producing sex hormones. They work by blocking other hormones that are required for sex hormone production. Gonadotropin-releasing hormone (GnRH) antagonists are a class of drugs that block the pituitary gland from producing hormones like follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

Market Dynamics: Drivers

Increasing prevalence of ovarian and prostate cancers

The rising prevalence of ovarian and prostate cancers propels the market growth. For instance, In the UK, more than 52,000 men are diagnosed with prostate cancer every year on average, that is 144 men every day. More than 44,000 men are diagnosed with prostate cancer every year in England. More than 10,000 men die from prostate cancer every year in England. More than 3,800 men are diagnosed with prostate cancer every year in Scotland. More than 1,000 men die from prostate cancer every year in Scotland. More than 2,800 are diagnosed with prostate cancer every year in Wales. Around 630 men die from prostate cancer every year in Wales.

Moreover, according to the World Cancer Research Fund International, ovarian cancer is the 18th most common cancer worldwide. It is the 8th most common cancer in women. There were more than 324,603 new cases of ovarian cancer in 2022. Around

206,956 women died of ovarian cancer. The rate of new cases of ovarian cancer was 10.2 per 100,000 women per year. The death rate was 6.0 per 100,000 women per year. Approximately 1.1 percent of women will be diagnosed with ovarian cancer at some point during their lifetime.

Restraints

Factors such as adverse effects and risks related to gonadotropin-releasing hormone agonists and antagonists are expected to hamper the market. In some cases, the usage of GnRH agonists and antagonists results in hot flashes, gynecomastia, fatigue, weight gain, fluid retention, erectile dysfunction, decreased libido, decrease in bone density, and irregular menstrual cycle.

Market Segment Analysis

The global GnRH agonists and antagonists drugs market is segmented based on drug type, application, end-user, and region.

The segment GnRH agonists accounted for approximately 43.6% of the global GnRH agonists and antagonists drugs market share

The GnRH agonists segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.

Gonadotropin-releasing hormone (GnRH) agonists work by temporarily switching off the ovaries by signaling the brain not to develop an egg. This causes the ovaries to stop producing estrogen and progesterone, which can help with a number of health conditions. GnRH agonists can help treat estrogen receptor-positive breast cancer cells by stopping the ovaries from producing estrogen. GnRH agonists can help thin the endometrium before endometrial ablation procedures

For instance, in June 2023, the US Food and Drug Administration approved the use of leuprolide acetate in a depot preparation, goserelin implant, and intranasal nafarelin for up to six months when administered alone for the treatment of symptomatic endometriosis.

Market Geographical Analysis

North America accounted for approximately 49.3% of the global GnRH agonists and antagonists drugs market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of prostate and ovarian cancers and endometriosis, and technological advancements among people, in this region, help to propel the market.

For instance, according to the U.S. Department of Health and Human Services, endometriosis happens when tissue similar to the lining of the uterus (womb) grows outside of the uterus. It may affect more than 11% of American women between 15 and 44. It is widespread among women in their 30s and 40s and may make it harder to get pregnant. Several different treatment options can help manage the symptoms and improve your chances of getting pregnant. Endometriosis affects an estimated 2 to 10 percent of American women between the ages of 25 and 40.

Moreover, according to an article published Centers for Disease Control and Prevention, based on the most recent data available, in the United States in 2022, 33,363 males died from prostate cancer. The rate of new cases of prostate cancer was 116.5 per 100,000 men per year. The death rate was 19.0 per 100,000 men per year. Approximately 12.8 percent of men will be diagnosed with prostate cancer at some point during their lifetime.

Market Segmentation

By Drug Type

GnRH Agonists

Leuprorelin

Goserelin

Triptorelin

Histrelin

Buserelin

GnRH Antagonists

Degarelix

Abarelix

Cetrorelix

Ganirelix

By Application

Gynecology

Oncology

Others

By End-User

Hospitals

Specialty Clinics

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global GnRH agonists and antagonists drugs market include Bayer AG, Ferring, Abbvie Inc., AstraZeneca, Merck KGaA, Ipsen Pharma, TerSera Therapeutics LLC, Takeda Pharmaceutical Company Limited, Cipla, Lupin among others.

Key Developments

In November 2023, Global pharma major Lupin Limited (Lupin) announced that it had received approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application for Ganirelix Acetate Injection, 250 mcg/0.5 mL Single-Dose Prefilled Syringe, to market a generic equivalent to the reference listed drug (RLD), of Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. Ganirelix is Lupin's first peptide-based injectable, strengthening the Company's commitment to innovative healthcare solutions.

Why Purchase the Report?

To visualize the global GnRH agonists and antagonists drugs market segmentation based on drug type, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global GnRH agonists and antagonists drugs market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global GnRH agonists and antagonists drugs market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Prostate and Ovarian Cancers
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects and Risks Related to GnRH Agonists and Antagonists
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Drug Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. GnRH Agonists*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. GnRH Antagonists

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Gynecology*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oncology
• 7.4. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Bayer AG*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Ferring
• 11.3. Abbvie Inc.
• 11.4. AstraZeneca
• 11.5. Merck KGaA
• 11.6. Ipsen Pharma
• 11.7. TerSera Therapeutics LLC
• 11.8. Takeda Pharmaceutical Company Limited
• 11.9. Cipla
• 11.10. Lupin (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us